These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 36198418)

  • 1. Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Benza RL; Langleben D; Hemnes AR; Vonk Noordegraaf A; Rosenkranz S; Thenappan T; Hassoun PM; Preston IR; Ghio S; Badagliacca R; Vizza CD; Lang IM; Meier C; Grünig E
    Eur Respir Rev; 2022 Dec; 31(166):. PubMed ID: 36198418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
    Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
    Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
    Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
    Ghofrani HA; Gomez Sanchez MA; Humbert M; Pittrow D; Simonneau G; Gall H; Grünig E; Klose H; Halank M; Langleben D; Snijder RJ; Escribano Subias P; Mielniczuk LM; Lange TJ; Vachiéry JL; Wirtz H; Helmersen DS; Tsangaris I; Barberá JA; Pepke-Zaba J; Boonstra A; Rosenkranz S; Ulrich S; Steringer-Mascherbauer R; Delcroix M; Jansa P; Šimková I; Giannakoulas G; Klotsche J; Williams E; Meier C; Hoeper MM;
    Respir Med; 2021 Mar; 178():106220. PubMed ID: 33540340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
    Gratsianskaya SE; Valieva ZS; Martynyuk TV
    Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
    Kenny M; Clarke MM; Pogue KT
    J Pharm Pract; 2022 Jun; 35(3):437-444. PubMed ID: 33084500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat for the treatment of pulmonary hypertension.
    Meis T; Behr J
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
    Kim NH
    Eur Respir Rev; 2010 Mar; 19(115):68-71. PubMed ID: 20956169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Mielniczuk LM; Swiston JR; Mehta S
    Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
    Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
    Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective.
    Mihalek AD; Scott CD; Mazimba S
    Vasc Health Risk Manag; 2022; 18():823-832. PubMed ID: 36299800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The soluble guanylate cyclase stimulator riociguat is the first-line therapy for chronic thromboembolic pulmonary hypertension patients].
    Valieva ZS; Gratsianskaya SE; Martynyuk TV
    Kardiologiia; 2020 Sep; 60(8):115-123. PubMed ID: 33155967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.
    Kim NH; D'Armini AM; Grimminger F; Grünig E; Hoeper MM; Jansa P; Mayer E; Neurohr C; Simonneau G; Torbicki A; Wang C; Fritsch A; Davie N; Ghofrani HA
    Heart; 2017 Apr; 103(8):599-606. PubMed ID: 28011757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
    Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
    Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY; Jiang X; Jing ZC
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
    Garnock-Jones KP
    Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riociguat: first global approval.
    Conole D; Scott LJ
    Drugs; 2013 Nov; 73(17):1967-75. PubMed ID: 24218053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Benza RL; Ghofrani HA; Grünig E; Hoeper MM; Jansa P; Jing ZC; Kim NH; Langleben D; Simonneau G; Wang C; Busse D; Meier C; Ghio S
    J Heart Lung Transplant; 2021 Oct; 40(10):1172-1180. PubMed ID: 34353714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.